{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:30:40Z","timestamp":1792683040732,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["SGR 01324 Q5856414G"],"award-info":[{"award-number":["SGR 01324 Q5856414G"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01640"],"award-info":[{"award-number":["PI21\/01640"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>We aimed to report the emergence of azole-resistant invasive aspergillosis in hematologic patients admitted to a tertiary hospital in Spain during the last 4\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Prospective, descriptive study was performed to describe and follow all consecutive proven and probable invasive aspergillosis resistant to azoles from hematological cohort during the last 4\u00a0months. All patients had fungal cultures and antifungal susceptibility or real-time PCR detection for <jats:italic>Aspergillus<\/jats:italic> species and real-time PCR detection for azole-resistant mutation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four cases of invasive aspergillosis were diagnosed in 4\u00a0months. Three of them had azole-resistant aspergillosis. Microbiological diagnosis was achieved in three cases by means of fungal culture isolation and subsequent antifungal susceptibility whereas one case was diagnosed by PCR-based aspergillus and azole resistance detection. All the azole-resistant aspergillosis presented TR34\/L98H mutation. Patients with azole-resistant aspergillosis had different hematologic diseases: multiple myeloma, lymphoblastic acute leukemia, and angioimmunoblastic T lymphoma. Regarding risk factors, one had prolonged neutropenia, two had corticosteroids, and two had viral co-infection. Two of the patients developed aspergillosis under treatment with azoles.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We have observed a heightened risk of azole-resistant aspergillosis caused by <jats:italic>A. fumigatus<\/jats:italic> harboring the TR<jats:sub>34<\/jats:sub>\/L98H mutation in patients with hematologic malignancies. The emergence of azole-resistant aspergillosis raises concerns for the community, highlighting the urgent need for increased surveillance and the importance of susceptibility testing and new drugs development.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s15010-024-02236-7","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T07:01:56Z","timestamp":1716793316000},"page":"1651-1656","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Report of three azole-resistant Aspergillus fumigatus cases with TR34\/L98H mutation in hematological patients in Barcelona, Spain"],"prefix":"10.1007","volume":"52","author":[{"given":"Patricia","family":"Monzo-Gallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Alastruey-Izquierdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Chumbita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso Francesco","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gallardo-Pizarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Peyrony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Teijon-Lumbreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Alcazar-Fuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateu","family":"Espasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Garcia-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"2236_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12281-023-00459-z","volume":"17","author":"D Bosetti","year":"2023","unstructured":"Bosetti D, Neofytos D. Invasive aspergillosis and the impact of azole-resistance. Curr Fungal Infect Rep. 2023;17:77\u201386.","journal-title":"Curr Fungal Infect Rep"},{"key":"2236_CR2","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3201\/eid2607.200088","volume":"26","author":"PPA Lestrade","year":"2020","unstructured":"Lestrade PPA, Buil JB, Van Der Beek MT, et al. Paradoxal trends in azole-resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013\u20132018. Emerg Infect Dis. 2020;26:1447\u201355.","journal-title":"Emerg Infect Dis"},{"key":"2236_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/myc.13426","volume":"65","author":"M Risum","year":"2022","unstructured":"Risum M, Hare RK, Gertsen JB, et al. Azole resistance in Aspergillus fumigatus. The first 2-year\u2019s data from the Danish National Surveillance Study, 2018\u20132020. Mycoses. 2022;65:419\u201328.","journal-title":"Mycoses"},{"key":"2236_CR4","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/cid\/ciy859","volume":"68","author":"PP Lestrade","year":"2019","unstructured":"Lestrade PP, Bentvelsen RG, Schauwvlieghe AFAD, et al. Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study. Clin Infect Dis. 2019;68:1463\u201371.","journal-title":"Clin Infect Dis"},{"key":"2236_CR5","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71:1367\u201376.","journal-title":"Clin Infect Dis"},{"key":"2236_CR6","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1128\/AAC.01092-06","volume":"51","author":"E Mellado","year":"2007","unstructured":"Mellado E, Garcia-Effron G, Alc\u00e1zar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51:1897\u2013904.","journal-title":"Antimicrob Agents Chemother"},{"key":"2236_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1128\/JCM.02478-15","volume":"54","author":"NP Wiederhold","year":"2016","unstructured":"Wiederhold NP, Gil VG, Gutierrez F, et al. First detection of TR34 L98H and TR46 Y121F T289A Cyp51 mutations in aspergillus fumigatus isolates in the United States. J Clin Microbiol. 2016;54:168\u201371.","journal-title":"J Clin Microbiol"},{"key":"2236_CR8","doi-asserted-by":"crossref","unstructured":"Alastruey-Izquierdo A, Alcazar-Fuoli L, Rivero-Men\u00e9ndez O, et al. Molecular identification and susceptibility testing of molds isolated in a prospective surveillance of triazole resistance in Spain (FILPOP2 Study) on behalf of the FILPOP2 Project from GEMICOMED (SEIMC) and REIPI. 2018.","DOI":"10.1128\/AAC.00358-18"},{"key":"2236_CR9","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1128\/AAC.02487-12","volume":"57","author":"P Escribano","year":"2013","unstructured":"Escribano P, Pel\u00e1ez T, Munoz P, Bouza E, Guinea J. Is azole resistance in Aspergillus fumigatus a problem in Spain? Antimicrob Agents Chemother. 2013;57:2815\u201320.","journal-title":"Antimicrob Agents Chemother"},{"key":"2236_CR10","doi-asserted-by":"publisher","first-page":"1170.e1","DOI":"10.1016\/j.cmi.2020.09.042","volume":"27","author":"P Escribano","year":"2021","unstructured":"Escribano P, Rodr\u00edguez-S\u00e1nchez B, D\u00edaz-Garc\u00eda J, et al. Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain. Clin Microbiol Infect. 2021;27:1170.e1-1170.e7.","journal-title":"Clin Microbiol Infect"},{"key":"2236_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jinf.2023.05.005","volume":"87","author":"P Puerta-Alcalde","year":"2023","unstructured":"Puerta-Alcalde P, Monz\u00f3-Gallo P, Aguilar-Guisado M, et al. Breakthrough invasive fungal infection among patients with haematologic malignancies: a national, prospective, and multicentre study. J Infect. 2023;87:46\u201353.","journal-title":"J Infect"},{"key":"2236_CR12","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S1473-3099(16)30138-4","volume":"16","author":"PE Verweij","year":"2016","unstructured":"Verweij PE, Zhang J, Debets AJM, et al. In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. Lancet Infect Dis. 2016;16:e251\u201360.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2236_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/cid\/ciad141","volume":"77","author":"S Huygens","year":"2023","unstructured":"Huygens S, Dunbar A, Buil JB, et al. Clinical impact of polymerase chain reaction\u2013based aspergillus and azole resistance detection in invasive Aspergillosis: a prospective multicenter study. Clin Infect Dis. 2023;77(1):338\u201345.","journal-title":"Clin Infect Dis"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02236-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02236-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02236-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T11:11:22Z","timestamp":1729681882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02236-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2236"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02236-7","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CG-V has received honoraria for talks on behalf of Gilead Science, Merck Sharp and Dohme, Pfizer, Jannsen, Novartis, Lilly, and a grant support from Gilead Science and Merck Sharp and Dohme. AS has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer, Novartis, Angelini, as well as grant support from Pfizer. OP has received honoraria for talks on behalf of MSD and Qiagen, and expertise for Sanofi.\u00a0PM-G has received honoraria for talks on behalf of Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants have consented to the submission of the brief report to the journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}